13F-HR filed by Abingworth LLP
Abingworth LLP filed this 13F-HR for the quarter ended 2017-12-31, filed 2018-02-14, with 17 holding rows worth $138,018,000.
- Accession
- 0000950123-18-001868
- Filer
- CIK 1397144
- Filed
- 2018-02-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2017
A holdings report, 17 entries on the cover page, a total value of $138,018,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $138,016,000 with VALUE read as thousands by filing date, 13F file number 028-14285. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| CRISPR THERAPEUTICS AG NAMEN AKT | H17182108 | Stock | 1,951,359 | $45,798,000 | thousands by filing date | |
| SIENTRA INC | 82621J105 | COM | 2,199,012 | $30,852,000 | thousands by filing date | |
| PARATEK PHARMACEUTICALS INC | 699374302 | Equity | 1,041,131 | $18,636,000 | thousands by filing date | |
| CYMABAY THERAPEUTICS INC | 23257D103 | COM | 1,147,077 | $10,553,000 | thousands by filing date | |
| ObsEva SA | H5861P103 | COM | 440,000 | $4,290,000 | thousands by filing date | |
| GTX INC DEL | 40052B207 | COM NEW | 339,174 | $4,280,000 | thousands by filing date | |
| PROTEON THERAPEUTICS INC | 74371L109 | COM | 2,017,872 | $3,733,000 | thousands by filing date | |
| CHIASMA INC | 16706W102 | COM | 2,080,595 | $3,433,000 | thousands by filing date | |
| CASCADIAN THERAPEUTICS INC | 14740B606 | COM NEW | 925,000 | $3,423,000 | thousands by filing date | |
| CELLECTIS ADS | 15117K103 | COM | 100,000 | $2,915,000 | thousands by filing date | |
| DERMIRA INC | 24983L104 | COM | 70,000 | $1,947,000 | thousands by filing date | |
| Ocugen | 43358V109 | Common | 888,889 | $1,804,000 | thousands by filing date | |
| ULTRAGENYX PHARMACEUTICAL IN | 90400D108 | COM | 38,100 | $1,767,000 | thousands by filing date | |
| ADAPTIMMUNE THERAPEUTICS PLC | 00653A107 | SPONDS ADR | 250,000 | $1,670,000 | thousands by filing date | |
| IMMUNE DESIGN CORP. | 45252L103 | Common Stock | 352,300 | $1,374,000 | thousands by filing date | |
| AURINIA PHARMACEUTICALS INC COM | 05156V102 | Stock | 252,129 | $1,142,000 | thousands by filing date | |
| LOMBARD MED INC | G55598109 | COM | 3,473,452 | $399,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000950123-18-001868 | this filing | 2018-02-14 | acceptance time not in the bulk data set |